Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 2;3(3):e200409.
doi: 10.1001/jamanetworkopen.2020.0409.

Assessment of Biomarker Testing for Lung Cancer Screening Eligibility

Tricia L Larose  1   2 , Filip Meheus  3 , Paul Brennan  1 , Mattias Johansson  1 , Hilary A Robbins  1
Affiliations

Assessment of Biomarker Testing for Lung Cancer Screening Eligibility

Tricia L Larose et al. JAMA Netw Open. .

Abstract

This exploratory study analyzes the cost-effectiveness of incorporating biomarkers into eligibility assessment for lung screening.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Incremental Cost-effectiveness Ratios for Biomarker-Informed Lung Screening Eligibility Based on Exploratory Cost-effectiveness Analysis
The reference scenario defines eligibility using a risk prediction model incorporating smoking and demographic information. Incremental cost-effectiveness ratios (ICERs) are shown as a function of (1) the percentage of future ever-smoking lung cancer cases classified as screening-eligible and (2) the per-person biomarker testing cost. The x-axis shows the percentage of ever-smoking lung cancer cases classified as screening-eligible (54% based on the US Preventive Services Task Force [USPSTF] guidelines, 62% based on smoking-model risk-based eligibility, and increases up to 80% based on hypothetical biomarker-informed eligibility). Individual curves represent ICERs based on hypothetical per-person biomarker costs ranging from $5 to $300. The dotted horizontal line indicates an ICER willingness-to-pay threshold of $50 000 per life-year gained.
See this image and copyright information in PMC

References

    1. Aberle DR, Adams AM, Berg CD, et al. ; National Lung Screening Trial Research Team . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):-. doi:10.1056/NEJMoa1102873 - DOI - PMC - PubMed
    1. Kovalchik SA, Tammemagi M, Berg CD, et al. . Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013;369(3):245-254. doi:10.1056/NEJMoa1301851 - DOI - PMC - PubMed
    1. Tammemägi MC, Katki HA, Hocking WG, et al. . Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728-736. doi:10.1056/NEJMoa1211776 - DOI - PMC - PubMed
    1. Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA. 2016;315(21):2300-2311. doi:10.1001/jama.2016.6255 - DOI - PMC - PubMed
    1. Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer Assessment of lung cancer risk on the basis of a biomarker panel of circulating proteins. JAMA Oncol. 2018;4(10):e182078. doi:10.1001/jamaoncol.2018.2078 - DOI - PMC - PubMed

Publication types